全文获取类型
收费全文 | 20616篇 |
免费 | 1681篇 |
国内免费 | 333篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 419篇 |
妇产科学 | 67篇 |
基础医学 | 2934篇 |
口腔科学 | 267篇 |
临床医学 | 1996篇 |
内科学 | 5461篇 |
皮肤病学 | 339篇 |
神经病学 | 277篇 |
特种医学 | 466篇 |
外科学 | 2174篇 |
综合类 | 2481篇 |
现状与发展 | 3篇 |
一般理论 | 1篇 |
预防医学 | 784篇 |
眼科学 | 123篇 |
药学 | 2474篇 |
8篇 | |
中国医学 | 2106篇 |
肿瘤学 | 201篇 |
出版年
2024年 | 42篇 |
2023年 | 467篇 |
2022年 | 732篇 |
2021年 | 878篇 |
2020年 | 843篇 |
2019年 | 848篇 |
2018年 | 814篇 |
2017年 | 848篇 |
2016年 | 794篇 |
2015年 | 673篇 |
2014年 | 1351篇 |
2013年 | 2326篇 |
2012年 | 1054篇 |
2011年 | 1158篇 |
2010年 | 841篇 |
2009年 | 953篇 |
2008年 | 905篇 |
2007年 | 940篇 |
2006年 | 798篇 |
2005年 | 647篇 |
2004年 | 569篇 |
2003年 | 412篇 |
2002年 | 398篇 |
2001年 | 337篇 |
2000年 | 301篇 |
1999年 | 311篇 |
1998年 | 275篇 |
1997年 | 211篇 |
1996年 | 212篇 |
1995年 | 199篇 |
1994年 | 166篇 |
1993年 | 167篇 |
1992年 | 144篇 |
1991年 | 100篇 |
1990年 | 109篇 |
1989年 | 70篇 |
1988年 | 63篇 |
1987年 | 70篇 |
1986年 | 77篇 |
1985年 | 76篇 |
1984年 | 88篇 |
1983年 | 42篇 |
1982年 | 74篇 |
1981年 | 48篇 |
1980年 | 34篇 |
1979年 | 33篇 |
1978年 | 25篇 |
1977年 | 29篇 |
1976年 | 18篇 |
1975年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2022,42(5):578-584
IntroductionThere is no consensus on the most appropriate treatment for chronic active antibody-mediated rejection (cAMR). Recent studies suggest that treatment with tocilizumab (TCZ) may stabilize graft function, decrease the intensity of donor-specific HLA antibodies (DSAs) and reduce inflammation of microcirculation.Patients and methodsObservational study with renal allograft recipients diagnosed with cAMR (n = 5) who had not submitted a response to traditional treatment based on the combination of plasma replacements, immunoglobulins, and rituximab. Patients were told to be treated with TCZ as compassionate use in six doses per month (8 mg/kg/month). Renal function, proteinuria, and the intensity of DSAs were monitored during follow-up.ResultsFive patients, average age 60 ± 13 years, three male and two retrasplants (cPRA average 55%) with preformed DSAs. Treatment with TCZ was initiated within 47 ± 52 days of biopsy. In two cases treatment was discontinued after the first dose, by severe bicitopenia with cytomegalovirus viremia and by graft failure, respectively. In the three patients who completed treatment, no stability of renal function (serum creatinine from 1.73 ± 0.70 to 2.04 ± 0.52 mg/dL, e-FGR 4 6 ± 15 to 36 ± 16 mL/min), showed increased proteinuria (3.2 ± 4.0 to 6.9 ± 11.0 g/g) and the intensity of DSAs maintain stable. No changes were observed in the degree of inflammation of microcirculation (g + pt 4.2 ± 0.8 vs. 4.3 ± 1.0) or in the degree of transplant glomerulopathy (cg 1.2 ± 0.4 vs. 1.8 ± 1.0).ConclusionsTCZ therapy does not appear to be effective in modifying the natural history of chronic active antibody-mediated rejection, does not improve the degree of inflammation of microcirculation and does not reduces the intensity of DSAs. 相似文献
2.
3.
4.
Heather L. Brown 《Journal of emergency nursing》2021,47(2):321-325
The coronavirus 2019 pandemic has affected almost every aspect of health care delivery in the United States, and the emergency medicine system has been hit particularly hard while dealing with this public health crisis. In an unprecedented time in our history, medical systems and clinicians have been asked to be creative, flexible, and innovative, all while continuing to uphold the important standards in the US health care system. To continue providing quality services to patients during this extraordinary time, care providers, organizations, administrators, and insurers have needed to alter longstanding models and procedures to respond to the dynamics of a pandemic. The Emergency Medicine Treatment and Active Labor Act of 1986, or EMTALA, is 1 example of where these alterations have allowed health care facilities and clinicians to continue their work of caring for patients while protecting both the patients and the clinicians themselves from infectious exposures at the same time. 相似文献
5.
《Journal of infection and chemotherapy》2022,28(4):587-590
A 37-year-old man developed right ankle pain and swelling six days after being diagnosed with coronavirus disease (COVID-19). Despite conservative treatment, his ankle symptoms persisted. Magnetic resonance imaging and computed tomography showed synovial hypertrophy and bone erosion in the ankle. Following arthroscopic synovectomy, performed 69 days after the COVID-19 diagnosis, the pain improved significantly. The clinical course was consistent with that of reactive arthritis following severe acute respiratory syndrome coronavirus 2 infection. The pathological findings resembled rheumatoid nodules. The bone erosion may have originated from the inflammatory pathway, which resembles the mechanism of rheumatoid arthritis. 相似文献
6.
Tofacitinib is an immunosuppressive and disease-modifying therapy in rheumatoid arthritis. It may result in many infections flaring up. It is important to take precautions of all kinds (cardiovascular, malignancy, infections etc.) before starting tofacitinib. In this article, we have highlighted important steps where we need to take precautions before starting tofacitinib. 相似文献
7.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
8.
Brittney H. Cotta Margaret F. Meagher Aaron Bradshaw Stephen T. Ryan Gerant Rivera-Sanfeliz 《Expert review of anticancer therapy》2019,19(4):301-308
Introduction: Percutaneous renal mass biopsy has evolved over the last decade with improvements on previous pitfalls including low tissue yield, high non-diagnostic rates, and complications. As understanding of tumor biology and natural history of renal cortical neoplasms has improved, percutaneous renal mass biopsy is poised to have an expanding role in an area characterized by individualized management and refined risk stratification.
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献
9.
10.